Every abortion enabled by the FDA's action cancels the state's ban
A federal appeals court in New Orleans has moved to sever one of the last remaining threads of nationwide abortion access, ruling that mifepristone may no longer be mailed to patients and must instead be dispensed only through in-person clinical visits. The decision unwinds pandemic-era expansions that had quietly become essential infrastructure for reproductive care — particularly in states where abortion is otherwise banned. In doing so, the court has overridden two decades of FDA scientific consensus, and set the stage for yet another defining confrontation at the Supreme Court over who holds authority over the body, the state, or the individual.
- The 5th Circuit's ruling doesn't merely restrict a drug — it dismantles the primary pathway through which abortion access has survived in ban states since 2022.
- Rural patients, low-income individuals, people with disabilities, and survivors of domestic violence face the sharpest consequences, as the in-person requirement erects barriers that are, for many, effectively insurmountable.
- The court chose to override the FDA's own two-decade scientific record, siding instead with Louisiana's assertion that mailed mifepristone directly cancels the state's abortion ban.
- The Trump administration's FDA has signaled a new safety review of the drug is underway, but cannot say when it will conclude — a cloud of uncertainty the appeals court cited in its reasoning.
- The ruling is almost certain to reach the Supreme Court, which unanimously protected mifepristone access in 2024 but now faces pressure to reconcile that precedent with a shifting political and legal landscape.
A federal appeals court in New Orleans has prohibited the mailing of mifepristone, the most commonly used abortion pill in America, ordering that it be dispensed only through in-person clinic visits. The ruling reverses FDA expansions made during the COVID-19 pandemic, which had allowed doctors to prescribe and mail the drug without requiring patients to appear in person.
Since the Supreme Court eliminated the federal right to abortion in 2022, mail-based prescriptions had become one of the few remaining avenues for abortion access — including in states with outright bans. The 5th Circuit's decision now closes that avenue, and will almost certainly be appealed to the Supreme Court.
Mifepristone has been FDA-approved since 2000 and was subject to strict controls for years before the agency, after reviewing extensive evidence, concluded the drug was safe enough to be prescribed remotely. The appeals court rejected that reasoning, quoting Louisiana's argument that the FDA's relaxed rules effectively nullified the state's abortion ban and its declaration that life begins at conception.
The Trump administration's FDA has acknowledged it is conducting a new safety review of the drug at the president's direction, but cannot say when it will be complete — a fact the court noted in its ruling. Notably, the panel chose to override the FDA's own accumulated scientific judgment, a significant departure from the traditional deference courts extend to regulatory agencies.
The human consequences will be immediate and unequal. Civil liberties attorneys warn the ruling will affect abortion and miscarriage care in every state, with the heaviest burden falling on those least able to absorb it: rural communities without nearby clinics, people living in poverty, individuals with disabilities, survivors of intimate partner violence, and communities of color.
The Supreme Court, which unanimously preserved mifepristone access in 2024, will now likely be forced to decide whether to uphold this new restriction — testing whether that earlier protection still holds under a changed political climate and a conservative majority.
A federal appeals court in New Orleans has moved to restrict one of the most widely used abortion methods in America by prohibiting the mailing of mifepristone, the pill that ends early pregnancies. The 5th U.S. Circuit Court of Appeals has ordered that the drug be dispensed only through in-person visits at clinics, reversing a significant expansion of access that took place during the pandemic.
The ruling comes at a moment when mail-based abortion prescriptions have become essential infrastructure for reproductive care. Since the Supreme Court eliminated the federal right to abortion in 2022, allowing states to enforce their own bans, sending the pill through the mail has emerged as one of the primary ways women access abortion—including in states where the procedure is otherwise prohibited. The court's decision will almost certainly be appealed to the Supreme Court, setting up another high-stakes confrontation over abortion access at the nation's highest court.
Mifepristone was approved by the FDA in 2000 as a safe and effective method for ending early pregnancies, typically used alongside a second medication called misoprostol. The drug was initially subject to strict controls: only specially certified doctors could prescribe it, and only after an in-person appointment where the patient would receive the pill directly. Those restrictions reflected concern about rare cases of excessive bleeding. But over more than two decades of monitoring and after reviewing dozens of studies involving thousands of women, FDA officials under President Joe Biden concluded the drug was safe enough to use without direct medical supervision. During the COVID-19 pandemic, the agency dropped both the prescriber certification requirement and the in-person dispensing requirement, allowing doctors to mail the pills to patients.
The appeals court's panel rejected this reasoning. In their ruling, the judges quoted Louisiana's argument that every abortion enabled by the FDA's relaxed rules "cancels Louisiana's ban on medical abortions and undermines its policy that 'every unborn child is a human being from the moment of conception and is, therefore, a legal person.'" Louisiana's attorney general and a woman claiming she was coerced into taking abortion pills had asked the court to roll back the FDA's regulations to their original, more restrictive form. A Louisiana federal judge had already ruled last month that the FDA's allowances conflicted with the state's abortion ban, though he stopped short of immediately undoing the regulations.
The Trump administration's FDA has signaled it is conducting a new review of mifepristone's safety at the president's direction. In court filings, the agency acknowledged it could not say when that review might be finished and admitted it was still gathering data. The appeals court judges noted this uncertainty in their decision.
Judges have traditionally deferred to the FDA's expertise on drug safety and regulation. But the 5th Circuit panel chose not to do so here, overriding two decades of the agency's accumulated evidence and its own prior judgments about the drug's safety profile.
The practical consequences will be immediate and uneven. Julia Kaye, a lawyer with the American Civil Liberties Union, said the ruling "is going to affect patients' access to abortion and miscarriage care in every state in the nation." When telemedicine options disappear, she noted, the burden falls hardest on those with the fewest resources: people in rural areas without nearby clinics, those living in poverty, people with disabilities, survivors of domestic violence, and communities of color.
The Supreme Court, which has a conservative majority, overturned the federal right to abortion in 2022 but then unanimously preserved access to mifepristone two years later. Now that same court will likely have to decide whether to uphold or overturn this appeals court ruling, forcing it to reconcile its own prior protection of the drug with the new restrictions being imposed by lower courts.
Notable Quotes
This is going to affect patients' access to abortion and miscarriage care in every state in the nation. When telemedicine is restricted, rural communities, people with low incomes, people with disabilities, survivors of intimate partner violence and communities of color suffer the most.— Julia Kaye, ACLU lawyer
The Hearth Conversation Another angle on the story
Why does it matter that this pill specifically can't be mailed? Aren't there other ways to access abortion?
After 2022, when the Supreme Court eliminated the federal right to abortion, mail prescriptions became the lifeline. In states with bans, you can't walk into a clinic. The pill in the mail was how women in those states could still access care. Without it, you need to travel, sometimes hundreds of miles, to a state where abortion is legal.
But the FDA said the pill was safe. Why would a court override that?
That's the tension at the heart of this. The FDA spent over twenty years studying mifepristone and concluded it was safe enough to use without a doctor watching. But the court sided with Louisiana's argument that the FDA's decision was really about enabling abortions in a state that banned them. The judges treated the safety question as secondary to the policy question.
What does the Trump administration have to do with this?
The FDA is now conducting a new review of the drug's safety at the president's direction. The court noted the agency can't even say when that review will finish. It's a way of keeping the question open, keeping pressure on the drug's availability.
Who gets hurt most by this?
Rural women, people without money for travel, people with disabilities who can't easily leave home, women escaping abusive partners who can't risk being seen at a clinic. The people who were already most vulnerable are the ones who depended on the mail option.
Will this actually stand?
Almost certainly it goes to the Supreme Court. But the Court's conservative majority is different now. They did protect mifepristone access unanimously in 2024, but that was before some of the current justices took office. No one knows what they'll do.